Daiichi Sankyo appointed former Novartis CMO John Tsai to lead its R&D efforts, signaling a strategic move to strengthen its drug development capabilities; this hiring highlights the industry's focus on experienced leadership in medical innovation.
Read the full article at FierceBiotech
This is a brief trending article summary.
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



